EZR and malignant colon neoplasm: We specifically confirmed a time-dependent increase in ezrin expression at the gene and protein levels in vemurafenib-resistant in comparison with vemurafenib-sensitive RKO colon cancer cells harbouring the BRAFV600E mutation under baseline conditions and after exposure to low concentration of vemurafenib.